title: Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas.
abstract: Ten patients with metastatic colorectal carcinoma were treated with MAb 17-1A (IgG2A). Before infusion, MAb was incubated in vitro with isolated autologous blood mononuclear cells. Treatment was given in repeated courses (2-4 times) to a maximum dose of 1000 mg of MAb 17-1A. One patient achieved a clinical complete remission, two patients had a minor response and one patient had stable disease for 5 months. The median survival for the four responders was 19 months compared to 7 months for the six non-responders. Therapy was well tolerated. In this series, 32 infusions of MAb 17-1A were given. The serum half-life of MAb 17-1A was approximately 22 hours. All patients developed anti-mouse antibodies of both IgG and IgM classes. No relation between adverse reactions and anti-mouse antibodies was seen. At 3 occasions allergic reactions were noted. Skin test with MAb 17-1A seems to reliably predict for allergic reactions.
authors.affiliation: Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
authors.forename: J E
authors.initials: JE
authors.lastname: Frödin
authors.forename: U
authors.initials: U
authors.lastname: Harmenberg
authors.forename: P
authors.initials: P
authors.lastname: Biberfeld
authors.forename: B
authors.initials: B
authors.lastname: Christensson
authors.forename: A K
authors.initials: AK
authors.lastname: Lefvert
authors.forename: A
authors.initials: A
authors.lastname: Rieger
authors.forename: J
authors.initials: J
authors.lastname: Shetye
authors.forename: B
authors.initials: B
authors.lastname: Wahren
authors.forename: H
authors.initials: H
authors.lastname: Mellstedt
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D003110:Colonic Neoplasms / Q000556:secondary / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000556:secondary / Q000628:therapy*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor